FDA "informal" rulemaking ban proposed by House Budget Committee.
This article was originally published in The Gray Sheet
FDA "INFORMAL RULEMAKING" PROHIBITION PROPOSED BY HOUSE BUDGET CMTE. in its report on the fiscal year 1996 budget resolution. "The FDA currently makes policy through a variety of improper means" such as "points to consider," draft guidances, speeches and warning letters, according to the report. These activities, which "are difficult to track, yet often contain substantive rules," should be eliminated by withholding funding for them through the appropriations process, the committee says.
You may also be interested in...
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Nutritional Brands rolls out NB Pure as brand, including logo, packaging design and website, for all its supplements after 25 years. “When you looked at our label for one brand and looked at the label for another brand, there was no symmetry between the two,” says CEO Danna Pratt.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.